The Challenges and Barriers to eCOA in Clinical Trials

Electronic clinical outcome assessments (eCOA) are digital tools used to capture patient-reported outcomes directly on electronic devices. As clinical trials move towards decentralized and hybrid models, eCOA has become central to collecting real-time, high-quality data across dispersed sites and remote participants, improving timeliness and increasing patient engagement.

However, the move to digital isn’t without its issues. Implementing eCOA can introduce several challenges that threaten compliance and data integrity if not managed carefully. Limitations in eCOA software – from poor usability to inadequate multi-language support – are becoming more prominent as trials decentralize and scale globally. This article offers a practical exploration of the most common barriers organizations face when implementing eCOA worldwide, and how they can be anticipated and mitigated.

Need More Support?

Contents

• What Is the Purpose of eCOA in Clinical Trials?
• Challenge #1: Technology & System Complexity
• Challenge #2: Patient Adoption & Engagement
• Challenge #3: Trial Site Readiness & Training
• Challenge #4: Regulatory & Compliance Barriers
• Challenge #5: Linguistic & Cultural Challenges in Global Trials
• Challenge #6: Operational Barriers
• Best Practices to Overcome eCOA Barriers

What Is the Purpose of eCOA in Clinical Trials?

The primary goal of eCOA in clinical trials is to capture accurate, timely, and patient-centered outcome data while reducing the administrative burden and variability associated with paper-based assessments. 

By enabling data to be recorded electronically, often in real-time and in patients’ everyday environments, eCOA aims to improve data quality and provide sponsors and regulators with more reliable insights into treatment efficacy and safety across diverse trial populations.

Challenge #1: Technology & System Complexity

Integrating eCOA Platforms

At both sponsor and site level, integrating eCOA platforms with existing trial technologies (such as wearable devices) can be technically demanding, particularly when systems are supplied by multiple vendors with differing data standards. Poor interoperability can lead to reconciliation challenges and increased manual oversight, undermining the efficiencies eCOA is intended to deliver.

Platform Usability

Platforms that are unintuitive or overly complex can discourage patient participation, increasing the risk of incomplete or inconsistent data capture. Decisions around device strategy further complicate implementation, with bring-your-own-device (BYOD) models raising compatibility and security concerns, while provisioned devices introduce logistical and cost pressures. 

When eCOA solutions become over-engineered in an attempt to accommodate every scenario, they can inadvertently increase operational burden, adding layers of complexity that strain resources and threaten compliance rather than simplifying trial execution.

Solutions to Challenge #1

• Build integration on standard APIs and data formats, and run end-to-end vendor integration testing early.
• Adopt a clear BYOD policy (eligibility, minimum specs, security) and reserve provisioned devices for high-risk cohorts.
• Simplify UX requirements to core workflows and use staged rollouts to reduce over-engineering.

Challenge #2: Patient Adoption & Engagement 

Diverse Patient Abilities

Clinical trial populations are often diverse, with wide variability in digital literacy, age, physical ability, and familiarity with mobile technology. For some participants, navigating electronic platforms can be intimidating or inaccessible, particularly where assessments are not designed with inclusivity in mind or fail to accommodate language proficiency or visual impairments.

Lack of Patient Engagement

Lengthy or complex assessments can lead to fatigue, reduced motivation, and ultimately non-compliance, especially in decentralized trials where direct site support is limited. Without intuitive interfaces and culturally appropriate, well-translated content, patient engagement can quickly deteriorate. Poor engagement not only increases the volume of missing data but can also introduce bias, compromising the reliability of trial outcomes and the interpretability of study results.

Solutions to Challenge #2

• Design short, readable prompts with plain language and clear on-screen instructions.
• Offer multiple participation options, such as audio prompts or assistive-device compatibility and simple technical support channels.
• Localize content and user flows to reflect cultural norms and reading levels.
• Provide patient-centered translations and localized guidance that improve comprehension and adherence in diverse populations.

Challenge #3: Trial Site Readiness & Training

Training & Capacity

Site staff need additional training to manage eCOA workflows and support patients remotely; training that competes with existing responsibilities. This move away from familiar paper-based or hybrid processes can produce uneven uptake across sites in multicenter studies and create variability in data quality. 

Protocol Amendments

Protocol amendments amplify the burden, with sites facing extra setup tasks, device logistics, re-training, and validation checks at precisely the busiest points in a study. Clear, concise documentation, role-specific training materials, and readily-available ongoing support are therefore essential to reduce friction and protect study timelines and data integrity.

Solutions to Challenge #3

• Deliver short, role-specific training modules that can be consumed on demand.
• Provide a dedicated helpdesk and simple escalation pathways during start-up and amendments.
• Translate and localize site-facing materials so training is consistent across regions.

Challenge #4: Regulatory & Compliance Barriers

Varying Regulatory Requirements

Regulatory and compliance complexity is a major pain point for eCOA deployment, particularly in global studies where expectations for system validation and data handling vary across countries. Sponsors must navigate differing requirements for eCOA validation, and IRB/ethics committee reviews can be prolonged when electronic assessments, device strategies, or translations change mid-study.

Maintaining Data Privacy

Data privacy and security – exemplified by GDPR, informed consent nuances, and cross-border data transfer rules – add further constraints that influence device selection and patient onboarding. Complete audit trails for assessments and translations, and region-specific documentation, are therefore essential to demonstrate compliance and to reduce delays or inconsistencies across trial sites.

Solutions to Challenge #4

• Map regulatory expectations per region and build validation plans that satisfy the strictest applicable standards.
• Keep full version control and auditable translation records for every language and update.
• Use documented consent flows tailored by jurisdiction to avoid data transfer complications.
• Supply traceable translations and maintain harmonized glossaries and translation memories to satisfy regulatory scrutiny and simplify audit evidence.

Challenge #5: Linguistic & Cultural Challenges in Global Trials

Misunderstandings From Poor Translations

Translating clinical outcome assessments requires preserving conceptual equivalence so that a question measures the same construct in every language. Poorly translated COAs – or translations that ignore cultural nuance – can change how patients understand response options and ultimately undermine data validity. Even small phrasing differences can change the interpretation of symptom severity or frequency, creating inconsistencies that bias pooled analyses or obscure true treatment effects.

The Demand for Linguistic Validation

Managing these risks across global studies demands rigorous linguistic validation and harmonization. Best practice includes expert reconciliation, cognitive debriefing with representative patients, and a centralized change-control process so amendments are spread correctly across every language version. Specialist teams experienced in clinical translations help keep versions aligned and protect data integrity, making linguistic expertise a non-negotiable component of any large-scale eCOA program.

Solutions to Challenge #5

• Apply formal linguistic validation and use consistent terminology glossaries across all languages.
• Centralize translation change control and use translation memory to accelerate updates and maintain consistency.
• Run small pilot cohorts in each language to check for unexpected cultural interpretation before full rollout, known as cognitive debriefing.
• Deliver end-to-end eCOA translation, manage harmonization and translation memory, and provide cognitive-debrief evidence to regulators.

Challenge #6: Operational Barriers

Late Content Changes

Late-stage protocol edits or wording changes are among the common operational headaches that affect eCOA builds. Even minor text tweaks can require reworking electronic forms, revalidating workflows, updating translations, and resubmitting materials to ethics committees – all of which can result in additional fees and delayed site activation. These knock-on effects can increase pressure on sites and potentially compromise patient recruitment windows.

Upfront Cost Concerns

While eCOA delivers clear long-term value, its upfront costs can feel significant – particularly when compared with traditional paper-based approaches. For large or complex studies, initial investment in eCOA development can run into the millions, compounded by additional costs for developing and validating new instruments before they are even approved for trial use.

Solutions to Challenge #6

• Document COA wording and involve all stakeholders during protocol drafting to avoid late rework.
• Use change-control windows and costed amendment plans to manage late edits without derailing timelines.
• Re-use validated instruments and existing translations where possible to reduce build and translation costs.

Best Practices to Overcome eCOA Barriers

Overcoming eCOA barriers starts with early, integrated planning. Engaging eCOA providers and clinical trial translation specialists during study design helps stabilize assessment content before development begins, reducing rework and unnecessary costs. A patient-centered approach, supported by clear language and culturally-appropriate content, also plays an important role in driving adoption and data completeness.

Key best practices for successful eCOA implementation include:

• Engaging eCOA and translation partners early to align assessment design, validation, and global rollout requirements.
• Prioritizing usability and patient-centered design, ensuring platforms are both accessible and easy to navigate.
• Ensuring linguistic clarity and conceptual equivalence across all language versions to protect data validity.
• Building scalable, well-governed processes for managing amendments, version control, and multi-language updates.
• Investing in robust training, validation, and quality assurance to meet regulatory expectations and maintain compliance.

Why Specialist Language Partners Are Critical to eCOA Success

Specialist partners are essential to executing these best practices at scale. Conversis supports sponsors and CROs through expert clinical trial and eCOA translation services, combining linguistic validation and rigorous quality assurance. By helping organizations manage complexity across many different languages and regulatory environments, our specialists enable smoother eCOA implementation while safeguarding data integrity throughout the trial lifecycle.

Ensure Compliance Through Our eCOA Translation Services

At Conversis, we provide specialist eCOA translation and linguistic validation services that preserve conceptual equivalence and maintain consistency across all languages. Contact our life science specialists today to reduce risk and protect data integrity throughout your clinical trial.

Contact Us

Explore Our eCOA Services